Haemonetics Corporation (HAE)

NYSE • Healthcare

$118.51

+$2.35 (+2.0%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$115.5

Previous Close$118.51

Day Range$115.49 - $119.2

Avg. Volume (3M)728K

Market Cap$5.3B

P/E Ratio57.5

52 Week Range

$48.98$123.77

Next EarningsIn 11 daysNov 5, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$339.3M100%

Gross Profitminus cost of goods$202.8M60%

Operating Incomeminus R&D and overhead$57.4M17%

Net Incomeminus taxes and the rest$33M10%

In plain terms: out of every $100 in revenue, Haemonetics Corporation keeps $10 as net profit.

Fundamentals & Financials

Revenue (TTM)

$1.3B

Net Income (TTM)

$96.2M

EPS (TTM)

$2.06

ROA (TTM)

4.07%

Current Ratio

3.08

Dividend Yield

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+8.9%Q3 2025$1.1

+13.4%Q4 2025$1.27

+3.1%Q1 2026$1.31

+0.8%Q2 2026$1.29

+5.6%Q3 2026$1.14

Nov 5

in 11 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Beat +5.6%

Haemonetics Corporation beat expectations on both the top and bottom line in the first fiscal quarter of 2027, reporting results on Aug. 6, as adjusted EPS of $1.14 topped the $1.08 estimate by 5.6% and revenue of about $339.4 million exceeded the $327.9 million consensus by 3.5%. Revenue rose 5.6% from about $321.4 million a year ago, with gross margin near 60% and operating margin near 17% as operating income came in at about $57.5 million. Net income slipped 3.0% to about $33.0 million, and operating cash flow was about $52.3 million. Consensus for the next period calls for adjusted EPS of $1.30 on revenue of $342.6 million.

Next report — what to expect

Haemonetics Corporation (HAE) reports next on November 5, 2026. Wall Street is looking for EPS of $1.29 on revenue of $345.1 million. For trailing context, revenue grew +5.6% year over year last quarter. HAE has beaten EPS in 8 of 8 most recent quarters, so attention may center on any change in that pattern.

View full earnings history

About Haemonetics Corporation

Haemonetics Corporation trades on the NYSE under HAE and makes blood and plasma collection, transfusion-management, and surgical blood-management equipment and software for healthcare providers. In FY2026, the company generated $1.3 billion in revenue. Founded in 1971, Haemonetics operates from Boston, Massachusetts and has been public since 1991.

Name

Haemonetics Corporation

CEO

Christopher A. Simon

Website

www.haemonetics.com

Industry

Healthcare

Year Founded

1971

Employees

3,009

Today's Snapshot

AI-generated

HAE closed 2% higher at 118.50, close to its 52-week high of 123.77. Earnings are due from HAE on 5 November.

Trading Volume

Below 10d avg (632.5K)

604.4K

vs S&P 500 Today

Outperforming Market

+2.53%

Updated: October 23, 2026 at 20:09 UTC

HAE Headlines

FDA clears Haemonetics’ PerQseal Elite

October 19, 2026

3 min read

View All News

Technical Indicators

5 Buy3 Neutral0 Sell

HAE shows a broadly bullish technical profile led by meaningful trend strength and long-term bullish positioning. ADX around 34.7 signals a strong directional trend while RSI sits above neutral and MACD is modestly positive, though short-term momentum is slightly soft. The stock trades well above its 200-day averages, and the nearby classic pivot near 116.97 provides a clear support reference. Volatility is moderate with an ATR near $3.5, while on-balance volume hints at some distribution that tempers conviction. Technical takeaway: Strong Buy — trend strength and above-200-day positioning support a bullish bias despite mixed short-term momentum.

All signals